Johnson & Johnson (NYSE:JNJ) Reaches New 12-Month High After Analyst Upgrade

Johnson & Johnson (NYSE:JNJ) reached a new 52-week high on Tuesday after Royal Bank Of Canada raised their price target on the stock from $240.00 to $255.00. Royal Bank Of Canada currently has an outperform rating on the stock. Johnson & Johnson traded as high as $231.19 and last traded at $230.82, with a volume of 8185063 shares. The stock had previously closed at $227.25.

A number of other research analysts have also recently issued reports on JNJ. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday, January 23rd. Argus boosted their target price on shares of Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Barclays increased their price target on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Wolfe Research raised their price target on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Finally, Raymond James Financial upped their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $233.73.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst upgrades and raised price targets are boosting investor sentiment — Bank of America raised its PT to $227 (from $221) and RBC raised its PT to $255 while keeping an Outperform rating, signaling confidence in JNJ’s outlook. BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here’s Why RBC Raises Price Target on Johnson & Johnson to $255
• Positive Sentiment: Clinical and commercial oncology updates are underpinning the longer‑term earnings thesis — recent ERLEADA and DARZALEX FASPRO data/updates are framed as material to JNJ’s oncology growth, and commentary expects oncology sales to roughly double over time. That bolsters the case for faster revenue/earnings ramp. ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story Johnson & Johnson’s Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy?
• Positive Sentiment: Product and medtech momentum: JNJ MedTech announced Varipulse updates and a new ultrasound catheter, and ACUVUE launched a novel daily multifocal toric contact lens in the UK/Ireland — both moves expand near‑term commercial catalysts and diversify growth drivers outside pharma. Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens
• Neutral Sentiment: Context piece: recent analysis highlights JNJ’s ~50% stock rally over the past nine months driven by improved earnings, product wins and legal progress — useful for sentiment context but not new company-specific catalyst. What’s Behind The 50% Surge In JNJ Stock?

Hedge Funds Weigh In On Johnson & Johnson

Several hedge funds have recently added to or reduced their stakes in JNJ. Abich Financial Wealth Management LLC bought a new stake in Johnson & Johnson in the third quarter valued at approximately $26,000. Cresta Advisors Ltd. bought a new stake in shares of Johnson & Johnson in the fourth quarter worth about $26,000. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $27,000. Clayton Financial Group LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth approximately $28,000. Finally, DecisionPoint Financial LLC boosted its holdings in shares of Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after buying an additional 75 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.5%

The business’s fifty day moving average is $212.27 and its 200 day moving average is $193.02. The firm has a market capitalization of $564.40 billion, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 2.26 and a beta of 0.35. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The firm had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. During the same quarter last year, the business posted $2.04 EPS. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.